141 related articles for article (PubMed ID: 21316103)
21. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
22. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
23. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
24. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
25. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
26. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
[No Abstract] [Full Text] [Related]
27. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
28. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
29. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
30. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
31. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Tchirkov A; Couderc JL; Périssel B; Goumy C; Regnier A; Uhrhammer N; Verrelle P; Berger M
Leukemia; 2006 Jan; 20(1):167-8. PubMed ID: 16270035
[No Abstract] [Full Text] [Related]
32. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
33. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
34. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
35. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
36. Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Langabeer SE; Crampe M; Haslam K; Kelly J; Cahill MR
Leuk Res; 2010 Jul; 34(7):e176-7. PubMed ID: 20153526
[No Abstract] [Full Text] [Related]
37. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
38. New-age drug meets resistance.
McCormick F
Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
[No Abstract] [Full Text] [Related]
39. Residual disease in chronic myeloid leukemia after induction of molecular remission.
Lange T; Niederwieser DW; Deininger MW
N Engl J Med; 2003 Oct; 349(15):1483-4. PubMed ID: 14534349
[No Abstract] [Full Text] [Related]
40. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
